(Q34409073)

2 August 2017

1 reference

title

Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now? (English)

1 reference

2 August 2017

1 reference

Ian C Scott

1

1 reference

2 August 2017

David L Scott

series ordinal

2

1 reference

2 August 2017

publication date

1 March 2014

1 reference

2 August 2017

1 reference

2 August 2017

volume

74

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

415-422

1 reference

Is there a future for small molecule drugs in the treatment of rheumatic diseases?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Novel small molecule therapeutics in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Mitogen-activated protein kinases in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

"Go upstream, young man": lessons learned from the p38 saga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Janus kinases in immune cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Structure and function of Syk protein-tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Biologics-based therapy for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0193-9

Signal transduction in rheumatoid arthritis

21 January 2018

1 reference

12 December 2020

Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud

1 reference

12 December 2020

Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

1 reference

12 December 2020

Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis

1 reference

12 December 2020

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist

1 reference

12 December 2020

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor

1 reference

12 December 2020

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

12 December 2020

OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy

1 reference

12 December 2020

10.1007/S40265-014-0193-9

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1003745936

0 references

Fatcat ID

release_6n4e7mwfrvhtzo7vtskbrmukqe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6n4e7mwfrvhtzo7vtskbrmukqe

24 November 2022

mapped directly with Wikidata item

1 reference